Related Experiment Video

Updated: Sep 4, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Successful therapy of chimeric antigen receptor T cells for isolated extramedullary acute lymphoblastic leukemia

Xiangqun Li1, Kylan Chen2, Xian Zhang3,4

  • 1Kecellitics Biotech Company Ltd Beijing China.

Ejhaem
|July 18, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Related Experiment Videos

Last Updated: Sep 4, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

Articles linked to this work by shared authors, journal, and citation graph.

Sarcomatoid malignancies with strong PD-L1 expression often represent dedifferentiated or undifferentiated melanomas.

Human pathology·2026

Data-Driven Trajectory Tracking Control Design for Unknown Linear Systems via a Nonminimal State-Space Model.

IEEE transactions on cybernetics·2026

Comparative analysis of multiple sclerosis burden in China and India from 1990 to 2021 based on the Global Burden of Disease Study 2021.

Immunologic research·2026

Case Report: Giant cell reparative granuloma of the humerus and femur-two rare cases with atypical skeletal involvement.

Frontiers in medicine·2026

The association of SPISE with cardiometabolic multimorbidity and stroke in middle-aged and older adults: a nationwide prospective cohort study.

Scientific reports·2026

Designing CeTiOx-based composite encapsulation overlayer on platinum for enhanced methanol steam reforming.

Journal of colloid and interface science·2026

A Germline ETV6 Missense Variant in a Family With Thrombocytopenia and Leukemia Predisposition: A Case Report.

EJHaem·2026

Somatic Mitochondrial-Nuclear DNA Transfer in Lymphoproliferative Disorders.

EJHaem·2026

Myeloma-Associated Sporadic Late-Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report.

EJHaem·2026

Acute Myeloid Leukaemia Driven by Rare HNRNPH1::ERG Fusion Gene in an Adult, With Distinct Transcripts Detected by RNASeq at Diagnosis and Relapse: A Case Report.

EJHaem·2026

Prescription Behaviour and Drug Interactions of Acid Suppressants With Tyrosine Kinase Inhibitors in Patients With Leukaemia: Data From Germany.

EJHaem·2026

Complement-Dominant Relapse of Mixed Autoimmune Hemolytic Anemia After Rituximab Response.

EJHaem·2026

Outcome-Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry.

Journal of the American Heart Association·2026

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

Cancer discovery·2026

Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.

Gastro hep advances·2026

Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.

Kidney international reports·2026

Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.

Frontiers in pharmacology·2026

FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation.

Mediterranean journal of rheumatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us